Biopharmaceutical Contract Research Organizations

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the biopharmaceutical CROs market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to CROs, featuring insights on the historical evolution of such organizations, legacy and contemporary trends in outsourcing activity. It further includes a brief introduction to the concept of CROs, featuring a discussion on the historical evolution of contract research services market in this domain. Additionally, it highlights details related to the various types of services offered by different CROs. Further, the chapter includes the advantages and risks related to partnering with contract service providers.

Chapter 4 features a detailed discussion on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing biologics. In addition, it includes information on the various factors that drive sponsors towards outsourcing and key parameters that sponsors must consider while choosing CROs across each phase of the drug development process.

Chapter 5 provides a detailed review of the overall landscape of the biopharmaceutical services market, highlighting the contributions of CROs, along with the information on year of establishment, company size, location of headquarters, A detailed assessment of the overall market landscape of about 200 CROs offering biopharmaceuticals based on a number of relevant parameters, such as  types of biologics (vaccines, cell therapies, gene therapies antibodies, recombinant proteins / peptides, vectors, biosimilars and others), scale of operation (clinical and preclinical) and types of services offered including [A] clinical services (trial management services, clinical data management, safety and pharmacovigilance services, regulatory services, consulting services and other clinical services) and [B] preclinical services (toxicology studies, in vivo studies, safety studies, PK / ADME and other bioanalytical Studies, consulting services, regulatory services, other preclinical services).  

Chapter 6 features elaborate profiles of prominent CROs engaged in offering biopharmaceutical related services. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details of their financial details / information (if available), service portfolio, and recent developments and an informed future outlook.

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across various services related to the development of biopharmaceuticals. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.  

Chapter 8 features an analysis of the various partnerships inked between CROs offering biopharmaceutical related services, which have been established. It includes a brief description on various types of partnerships models (such as outsourcing agreements, licensing agreements, and service alliances) that have been employed by stakeholders in this domain since 2016.

Chapter 9 presents insights from a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2016-2020. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition, geographical location of the companies, and types of biologics.

Chapter 10 features a proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

Chapter 11 features a comprehensive market forecast analysis, highlighting the likely growth of cell and gene therapy CROs market, for the time period 2021-2030. In order to provide details on the future outlook, our projections have been segmented on the basis of [A] types of biologics (vaccines, cell therapies, gene therapies, antibodies, recombinant proteins / peptides and others) [B] scale of operation (clinical and preclinical), [C] target therapeutic areas (oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas) and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).

Chapter 12 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall biopharmaceutical research services industry.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of survey transcript(s) of the discussions that were held key stakeholders in the industry. 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report. 

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report. 

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3 Introduction
3.1. Chapter Overview
3.2. Overview of Biologics
3.2.1. Types of Biologics

3.3. Overview of Contract Research Organizations (CROs)
3.4. Evolution of CROs
3.5. Classification of CROs
3.6. Services Offered by CROs
3.7. Advantages of Outsourcing Operations to CROs
3.8. Risks Associated with Outsourcing Operations to CROs

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Biologics Research

4.3. Models of Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Model

4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach

4.5. Selecting a CRO Partner
4.5.1. Key Considerations for Outsourcing Biologics-related Operations

4.6. Role of CROs in the Drug Development Process
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services

4.7. Conclusion

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Biopharmaceutical CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
5.2.2. Analysis by Scale of Operation

5.3. Preclinical Biopharmaceutical CROs
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size 
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Biologic 
5.3.5. Analysis by Type of Services Offered 

5.4. Clinical Biopharmaceutical CROs
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Analysis by Type of Biologics
5.4.5. Analysis by Type of Services Offered

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Biocon
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Services Portfolio
6.2.4. Future Outlook

6.3. Covance
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Financial Information
6.3.4. Future Outlook

6.4. ICON
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Future Outlook

6.5. Medpace
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Future Outlook

6.6. Pharmaron
6.6.1. Company Overview
6.6.2. Services Portfolio
6.6.3. Future Outlook

6.7. PPD
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Financial Information
6.7.4. Future Outlook

6.8. PRA Health Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Service Portfolio
6.8.4. Future Outlook

6.9. Syneos Health
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Services Portfolio
6.9.4. Future Outlook

6.10. Vimta Labs
6.10.1. Company Overview
6.10.2. Services Portfolio
6.10.3. Financial Information
6.10.4. Future Outlook

6.11. WuXi AppTec
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Service Portfolio
6.11.4. Future Outlook

7. BENCHMARK ANALYSIS
7.1. Chapter Overview 
7.2. Methodology 
7.3. Benchmark Analysis: Peer Groups 
7.3.1. Peer Group I 
7.3.2. Peer Group II 
7.3.3. Peer Group III 
7.3.4. Peer Group IV 
7.3.5. Peer Group V
7.3.5. Peer Group VI
7.3.5. Peer Group VII
7.3.5. Peer Group VIII

8. PARTNERSHIPS AND COLLABORATIONS 
8.1. Chapter Overview
8.2. Partnership Models

8.3. Biopharmaceutical CROs: Recent Partnerships and Collaborations 
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership Model
8.3.2.1. Analysis by Year of Partnership and Type of Partnership Model

8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Analysis by Scale of Operation
8.3.5. Analysis by Geography
8.3.5.1. Country-wise Analysis
8.3.5.2. Intercontinental and Intracontinental Agreements

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models

9.3. Biopharmaceutical CROs: Mergers and Acquisitions
9.3.1. Analysis by Year of Acquisition
9.3.2. Analysis by Type of Collaboration
9.3.3. Analysis by Geography
9.3.3.1. Continent-wise Distribution
9.3.3.2. Country-wise Distribution
9.3.4 Ownership Change Matrix
9.3.5. Most Active Acquirers: Analysis by Number of Acquisitions

9.4. Distribution by Key Value Drivers
9.4.1 Analysis by Key Value Drivers
9.4.2 Analysis by Key Value Drivers and Year of Acquisitions
9.5. Valuation Analysis: Acquisition Deal Multiples

10. ATTRACTIVENESS COMPETATIVENESS MATRIX
10.1. Chapter Overview

10.2. AC Matrix: Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment

10.3. Analytical Methodology
10.4. AC Matrix: Contract Manufacturing Scenario in North America
10.5. AC Matrix: Contract Manufacturing Scenario in Europe
10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions

11.3. Global Biopharmaceutical CROs Market
11.3.1. Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
11.3.2. Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
11.3.3. Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
11.3.4. Global Biopharmaceutical CROs Market: Distribution by Geography

11.4. Biopharmaceutical CROs Market in North America
11.4.1. Biopharmaceutical CROs Market in North America: Distribution by Therapeutic Area
11.4.1.1. Biopharmaceutical CROs Market for Oncological Disorders in North America, 20212030
11.4.1.2. Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, 2021-2030
11.4.1.3. Biopharmaceutical CROs Market for Inflammatory Disorders in North America, 2021-2030
11.4.1.4. Biopharmaceutical CROs Market for Neurological Disorders in North America, 2021-2030
11.4.1.5. Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, 2021-2030
11.4.2. Biopharmaceutical CROs Market in North America: Distribution by Scale of Operation
11.4.2.1. Biopharmaceutical CROs Market for Preclinical Operations in North America, 2021-2030
11.4.2.2. Biopharmaceutical CROs Market for Clinical Operations in North America, 2021-2030

11.5. Biopharmaceutical CRO Services Market in Europe
11.5.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Europe
11.5.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Europe, 2021-2030
11.5.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Europe, 2021-2030
11.5.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Europe, 2021-2030
11.5.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Europe, 2021-2030
11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Europe, 2021-2030

11.5.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Europe
11.5.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Europe, 2021-2030
11.5.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Europe, 2021-2030

11.6. Biopharmaceutical CRO Services Market in Asia-Pacific
11.6.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Asia-Pacific
11.6.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Asia-Pacific, 2020-2030
11.6.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
11.6.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Asia-Pacific, 2020-2030
11.6.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Asia-Pacific, 2020-2030
11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030
11.6.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Asia-Pacific
11.6.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Asia-Pacific, 2020-2030
11.6.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Asia-Pacific, 2020-2030

11.7. Biopharmaceutical CRO Services Market in Latin America
11.8. Biopharmaceutical CRO Services Market in Middle East North America

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors

13. CONCLUDING REMARKS
13.1. Chapter Overview

14. SURVEY TRANSCRIPTS

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Biologics
Figure 3.2 Stages of the Drug Development Process
Figure 3.3 Commonly Offered Services by CROs
Figure 3.4 Advantages of Outsourcing Operations to CROs
Figure 3.5 Risks Associated with Outsourcing Operations to CROs
Figure 4.1 Guiding Models for Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome based Business Model
Figure 4.4 Steps to Consider before Outsourcing
Figure 4.5 Key Considerations while Selecting a CRO Partner
Figure 4.6 Role of CROs in the Drug Development Process
Figure 5.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Figure 5.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Figure 5.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Figure 5.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Figure 5.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Figure 5.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Figure 5.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Figure 5.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 5.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Figure 5.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
Figure 5.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Figure 5.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Figure 5.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Figure 5.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Figure 5.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Figure 6.1 Biocon: Annual Services Revenues, 2016 – 9M 2020 (INR Billion)
Figure 6.2 Biocon: Service Portfolio
Figure 6.3 Covance: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.4 Covance: Service Portfolio
Figure 6.5 ICON: Annual Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.6 ICON: Service Portfolio
Figure 6.7 Medpace: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.8 Medpace: Service Portfolio
Figure 6.9 Medpace: Regulatory Affair Capabilities
Figure 6.10 Pharmaron: Service Portfolio
Figure 6.11 PPD: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.12 PPD: Service Portfolio
Figure 6.13 PRA Health Sciences: Annual Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.14 PRA Health Sciences: Service Portfolio
Figure 6.15 Syneos Health: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.16 Syneos Health: Service Portfolio
Figure 6.17 Vimta Labs: Annual Service Revenues, 2016 – 9M 2020 (INR Billion)
Figure 6.18 Vimta Labs: Service Portfolio
Figure 6.19 WuXi App Tec: Annual Services Revenues, 2016 – 9M 2020 (USD Billion)
Figure 6.20 WuXi App Tec: Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Company Size and Location of Headquarters
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership Model
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
Figure 8.4 Most Active Players: Distribution by Number of Partnerships
Figure 8.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 8.6 Partnerships and Collaborations: Distribution by Geography
Figure 8.7 Partnerships and Collaborations: Country-Wise Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (2016- 2020)
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Figure 9.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
Figure 9.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 9.5 Mergers and Acquisitions: Region-wise Distribution
Figure 9.6 Mergers and Acquisitions: Country-wise Distribution
Figure 9.7 Mergers and Acquisitions: Ownership Change Matrix
Figure 9.8 Mergers and Acquisitions: Key Value Drivers
Figure 9.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 9.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Figure 10.1. AC Matrix: Pictorial Representation
Figure 10.2. AC Matrix: Positioning of Different Biologics in North America
Figure 10.3. AC Matrix: Positioning of Different Biologics in Europe
Figure 10.4. AC Matrix: Positioning of Different Biologics in Asia Pacific
Figure 11.1 Biopharmaceutical CROs: Market Forecast Methodology
Figure 11.2 Global Biopharmaceutical CROs Market, 2021-2030
Figure 11.3 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics, 2021 and 2030
Figure 11.4 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 11.5 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation, 2021 and 2030
Figure 11.6 Global Biopharmaceutical CROs Market: Distribution by Geography, 2021 and 2030
Figure 11.7 Biopharmaceutical CROs Market in North America, 2021-2030 (USD Million)
Figure 11.8 Biopharmaceutical CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 11.9 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 11.10 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Figure 11.11 Biopharmaceutical CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 11.12 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 11.13 Biopharmaceutical CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 11.14 Biopharmaceutical CROs Market for Clinical Operations in North America, 2021-2030 (USD Million
Figure 11.15 Biopharmaceutical CROs Market in Europe, 2021-2030 (USD Million)
Figure 11.16 Biopharmaceutical CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 11.17 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 11.18 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Figure 11.19 Biopharmaceutical CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 11.20 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 11.21 Biopharmaceutical CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 11.22 Biopharmaceutical CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 11.23 Biopharmaceutical CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.24 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.25 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.26 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.27 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.28 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.29 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.30 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 11.31 Biopharmaceutical CROs Market in Latin America, 2021-2030 (USD Million)
Figure 11.32 Biopharmaceutical CROs Market in Middle East North Africa, 2021-2030 (USD Million)
Figure 11.33 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 12.1 Biopharmaceutical CROs SWOT Analysis: Overview
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Concluding Remarks: Current Market Landscape for Preclinical Biopharmaceutical CROs
Figure 13.2 Concluding Remarks: Current Market Landscape for Clinical Biopharmaceutical CROs
Figure 13.3 Concluding Remarks: Recent Partnerships
Figure 13.4 Concluding Remarks: Mergers and Acquisitions
Figure 13.5 Concluding Remarks: Clinical Trial Analysis
Figure 13.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Attributes of Transactional Outsourcing Based Business Model
Table 4.2 Comparison of Key Factors Considered by Biologic Developers for Selecting a CRO Partner: Harvey Ball Analysis
Table 5.1 Biopharmaceutical CROs: Information on Year of Establishment, Location of Headquarters, Company Size and Types of Biologics
Table 5.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
Table 5.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
Table 6.1 Biocon: Company Overview
Table 6.2 Biocon: Future Outlook
Table 6.3 Covance: Company Overview
Table 6.4 Covance: Future Outlook
Table 6.5 ICON: Company Overview
Table 6.6 ICON: Future Outlook
Table 6.7 Medpace: Company Overview
Table 6.8 Medpace: Future Outlook
Table 6.9 Pharmaron: Company Overview
Table 6.10 Pharmaron: Future Outlook
Table 6.11 PPD: Company Overview
Table 6.12 PPD: Future Outlook
Table 6.13 PRA Health Sciences: Company Overview
Table 6.14 PRA Health Sciences: Future Outlook
Table 6.15 Syneos Health: Company Overview
Table 6.16 Syneos Health: Future Outlook
Table 6.17 VIMTA Labs: Company Overview
Table 6.18 WuXi App-Tec: Company Overview
Table 6.19 WuXi App Tec: Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Partnerships and Collaborations: List of Agreements, 2016-2021
Table 9.1 Mergers and Acquisitions: List of Mergers / Acquisitions, 2016 - 2020
Table 9.2 Mergers and Acquisitions: Information on Key Value Drivers, 2016- 2020
Table 9.3 Mergers and Acquisitions: Deal Multiples, 2016- 2020
Table 15.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 15.2 Biopharmaceutical CROs: Distribution by Scale of Operation
Table 15.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
Table 15.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
Table 15.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
Table 15.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
Table 15.8 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
Table 15.9 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
Table 15.10 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types Services Offered
Table 15.11 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
Table 15.12 Biopharmaceutical Clinical CROs: Distribution by Company Size
Table 15.13 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
Table 15.14 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
Table 15.15 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
Table 15.16 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
Table 15.17 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
Table 15.18 Biocon: Annual Service Revenues, 2016 – 9M 2020 (INR Billion)
Table 15.19 Covance: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.20 ICON: Annual Revenues, 2016 - 9M 2020 (USD Billion)
Table 15.21 Medpace: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.22 PPD: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.23 PRA Health Sciences: Annual Revenues, 2016 - 9M 2020 (USD Billion)
Table 15.24 Syneos: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.25 Vimta Labs: Annual Service Revenues, 2016 – 9M 2020 (INR Billion)
Table 15.26 WuXi AppTec: Annual Service Revenues, 2016 – 9M 2020 (USD Billion)
Table 15.27 Partnerships and Collaborations: Distribution by Year of Partnership
Table 15.28 Partnerships and Collaborations: Distribution by Type of Partnership Model
Table 15.29 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
Table 15.30 Most Active Players: Distribution by Number of Partnerships
Table 15.31 Partnerships and Collaborations: Distribution by Scale of Operation
Table 15.32 Partnerships and Collaborations: Distribution by Geography
Table 15.33 Partnerships and Collaborations: Country-Wise Distribution
Table 15.34 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.35 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (2016- 2020)
Table 15.36 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
Table 15.37 Mergers and Acquisitions: Distribution by Year and Type of Agreement
Table 15.38 Mergers and Acquisitions: Continent-wise Distribution
Table 15.39 Mergers and Acquisitions: Continent-wise Distribution
Table 15.40 Mergers and Acquisitions: Country-wise Distribution
Table 15.41 Mergers and Acquisitions: Ownership Change Matrix
Table 15.42 Mergers and Acquisitions: Key Value Drivers
Table 15.43 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 15.44 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 15.45 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
Table 15.46 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics, 2021 and 2030
Table 15.47 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Table 15.48 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation, 2021 and 2030
Table 15.49 Global Biopharmaceutical CROs Market: Distribution by Geography, 2021 and 2030
Table 15.50 Biopharmaceutical CROs Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.51 Biopharmaceutical CROs Market for Oncological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.52 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.53 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.54 Biopharmaceutical CROs Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.55 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.56 Biopharmaceutical CROs Market for Preclinical Operations in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.57 Biopharmaceutical CROs Market for Clinical Operations in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.58 Biopharmaceutical CROs Market in Europe, 2021-2030 (USD Million)
Table 15.59 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.60 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 15.61 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.62 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.63 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.64 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.65 Biopharmaceutical CROs Market for Clinical Operations in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.66 Biopharmaceutical CROs Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.67 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.68 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.69 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.70 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.71 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.72 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.73 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.74 Biopharmaceutical CROs Market for Preclinical Operations in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.75 Biopharmaceutical CROs Market for Preclinical Operations in Middle East North Africa, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.76 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

1. 4Clinics
2. Abiogenesis Clinpharm
3. Accelovance
4. Accelsiors
5. Accutest
6. acromion
7. Advanced Clinical
8. Aesculape CRO 
9. Alderley Analytical
10. Alliance Pharma
11. Allied Clinical Management
12. Almirall
13. Altasciences
14. Amarex Clinical Research
15. AOBiome
16. APEIRON Biologics
17. Aqlivia
18. ARVYS Proteins
19. AstraZeneca
20. Auriga Research
21. Aurigon
22. Avania
23. Beaufort
24. Biocon
25. BioGeneration Ventures
26. Biomere
27. Bioneeds
28. Biotrend
29. Bit Bio
30. BrainStorm Cell Therapeutics
31. BSL Bioservice
32. BTS Research
33. Catalyst Clinical Services
34. CATO SMS
35. Celgene
36. CellTrans
37. Charles River Laboratories
38. ChemPartner
39. Cliantha
40. Clinartis
41. ClinChoice
42. Clindataceutics 
43. Clinexa Life Sciences
44. Clinfomatrix
45. Clinipace
46. ClinSmart
47. Cmed
48. Cobridge
49. COD Research
50. CombiGene
51. Confidence Pharmaceutical Research
52. Covance
53. CPL Biologicals
54. CR2O
55. CRC Oncology
56. Crown Bioscience
57. CSSi LifeSciences
58. CTI
59. Cynbiose
60. Diamond Pharma Services
61. DiscGenics
62. dMed Biopharmaceutical
63. DP Clinical
64. DuPage Medical
65. EMMES
66. Ergomed
67. ethica CRO
68. Eubiologics
69. Everest Clinical Research
70. Evotec
71. Excelya
72. Fast-Track Drugs and Biologics
73. FGK Clinical Research
74. FHI Clinical
75. Fios Genomics
76. Forbion
77. Frontage
78. Geistek Pharma
79. Genelife Clinical Research
80. GeneMedicine
81. Generic Specialties
82. Genesis Biotechnology
83. Geneticist
84. GeneWerk
85. GenoSafe
86. Genprex
87. Gladstone
88. Guosa Life Sciences
89. GVK BIO
90. Harbour BioMed
91. Heidelberg Pharma
92. Hubrecht Organoid Technology
93. ICON
94. Immunicum
95. ImmunoPrecise Antibodies
96. ImQuest BioSciences
97. Innovaderm
98. Insignia Clinical Services
99. InteRNA Technologies
100. International Vaccine Institute
101. IQVIA
102. IRBM
103. Iris Pharma
104. Johnson County Clin-Trials
105. JSR Life Sciences
106. KCR
107. Klinar CRO
108. Lambda Therapeutic Research
109. LatinaBA
110. Lava Therapeutics
111. Linical
112. LINK Medical
113. Lonza
114. Lovelace Biomedical
115. LSK Global Pharma Service
116. Magenta Therapeutics
117. MCRA
118. Medidee
119. Medpace
120. MetabAxis
121. Milner Therapeutics Institute
122. Mithra Biotechnology
123. MKR Clinical Research Consultants
124. MTZ Clinical Research
125. NBE Therapeutics
126. Neozene
127. NetValue BioConsulting
128. Nexelis
129. NEXT Oncology
130. Noble Life Sciences
131. Nutrasource
132. Nuvisan
133. OncoBay Clinical
134. Open Orphan
135. Oxford BioTherapeutics
136. Palm Beach CRO
137. Pepgra
138. Pfizer
139. Pharma Models
140. Pharmaron
141. Pharmaseed
142. PharmOut
143. Phoenix Clinical Research
144. PPD
145. PRA Health Sciences
146. PRC Clinical
147. Precision For Medicine
148. Prestige BioPharma
149. Prince William Science Accelerator
150. Prodia the CRO
151. ProRelix Research
152. PSN Research
153. QAscent Research Solutions
154. QPS
155. Q-Trials
156. Quad-C Management
157. QUADRO CRO
158. Quality by Design (QbD)
159. Quanticate
160. Radyus Research
161. RCT
162. Renova Therapeutics
163. Rho
164. RiboBio
165. RTI Health Solutions 
166. RTI International
167. SanaClis
168. Sandoz
169. Sanyou Biopharmaceuticals
170. SBH Sciences
171. SCiAN Services
172. Scope International
173. Secarna Pharmaceuticals
174. SEKISUI XenoTech
175. Sernova
176. Simbec-Orion
177. SMS-oncology
178. STATKING Clinical Services
179. Strategic Preclinical Product Development (S2PD)
180. Svar Life Science
181. Symbion Research International
182. Symeres
183. Syneos Health
184. Takeda
185. Technical Resources International
186. The Geneva Foundation
187. The Smerud Medical Research
188. Therapeutics
189. Tonic Bioventures
190. Tranz-Life
191. VaxTrials
192. Veeda Clinical Research
193. Veristat
194. Vimta Labs
195. Virginia Contract Research Organization
196. VisMederi
197. Vium
198. Vivotecnia
199. Washington Biotechnology
200. WCCT
201. Worldwide Clinical Trials
202. WuXi AppTec
203. Xcene Research